Ding Yang
Podiatrist · Flushing, NYNPI 1417127705
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Elite Orthopedics, LLC at 45.4% of the total. Reporting peaked in 2019 at $3,360 and has fallen 76.8% since, to $779 in 2025. Among podiatrist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $85.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elite Orthopedics, LLC$3K
- Advanced Oxygen Therapy Inc.$1K
- Acumed LLC$491
- IBSA Pharma Inc.$464
- Kerecis Limited$322
- Smith+Nephew$305
- plus $1K from 8 others
What the payments were for
- Travel & lodging$1883%
- Food & beverage$3,60652%
- Education$3,15745%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elite Orthopedics, LLC | 1 | $3,157 |
| Advanced Oxygen Therapy Inc. | 15 | $1,042 |
| Acumed LLC | 4 | $491 |
| IBSA Pharma Inc. | 24 | $464 |
| Kerecis Limited | 3 | $322 |
| Smith+Nephew | 18 | $305 |
| Stryker | 5 | $296 |
| Paragon 28, Inc. | 2 | $203 |
| Organogenesis Inc. | 4 | $203 |
| Medshape, Inc. | 1 | $188 |
| Royal Biologics, Inc. | 1 | $149 |
| Medtronic | 1 | $91 |
| Vertex | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$708
- Topical oxygen chamber for extremities$562
- ACUMED$458
- OsteoMed$244
- Kerecis Omega3 SurgiClose$236
- Kerecis Omega3 GraftGuide$236
- DynaNail$188
- CITREFIX$172
- PuraPly$153
- Fibrinet$149
- Amniotic Membranes$143
- R3ACT$132
- Licart$104
- FLECTOR$104
How this compares
$6,951 in reported general payments places this provider in the 90th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 2,310 | $1,522,921 |
| CiclopiroxCiclopirox Olamine | 2,654 | $99,566 |
| Ketoconazole | 1,767 | $71,917 |
| Halobetasol Propionate | 826 | $61,905 |
| Diclofenac Sodium | 254 | $48,672 |
| Clobetasol Propionate | 725 | $45,796 |
| Oxiconazole Nitrate | 118 | $44,807 |
| Lidocaine | 567 | $29,908 |
| Ammonium Lactate | 966 | $27,525 |
| Diflorasone Diacetate | 64 | $25,661 |
| LicartDiclofenac Epolamine | 26 | $21,434 |
| Terbinafine Hcl | 1,983 | $21,096 |
| Tavaborole | 44 | $14,850 |
| Naftifine Hcl | 71 | $11,849 |
| Fluorouracil | 125 | $10,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| IBSA Pharma Inc.Licart | $464 | $21,43426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 862 podiatrist providers in New York.
Other podiatrist in Flushing
- Charles LombardiFlushing$7K
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.